심방세동 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global atrial fibrillation market size is expected to reach USD 90.52 Billion in 2034 from USD 36.20 Billion in 2025, growing at a CAGR of 10.72% during 2026-2034.The global atrial fibrillation (AF) market is witnessing significant growth due to increasing prevalence of cardiovascular disorders worldwide. AF is one of the most common heart rhythm abnormalities, particularly among aging populations. Rising awareness, improved diagnostic techniques, and expanding treatment options are driving market expansion.

Key growth drivers include development of novel anticoagulants, catheter ablation technologies, and wearable cardiac monitoring devices. Increasing healthcare investments and early screening initiatives further support market growth. However, high treatment costs and limited access to advanced care in certain regions may present challenges.

Looking ahead, continued research into innovative therapies and digital health integration will enhance patient management. Growing emphasis on preventive cardiology is expected to sustain long-term demand in the atrial fibrillation market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment type

• Pharmacological Treatment
• Non-Pharmacological Treatment

By End-Use

• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Medtronic, Johnson & Johnson, Abbott, Boston Scientific, Biotronik, Philips, Siemens Healthineers, GE HealthCare, Stryker, iRhythm Technologies, AliveCor, Biosense Webster, Acutus Medical, AtriCure, Kardium, Affera, Baylis Medical, CathWorks, Pulse Biosciences, Sanofi

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ATRIAL FIBRILLATION MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Pharmacological Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Pharmacological Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ATRIAL FIBRILLATION MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ATRIAL FIBRILLATION MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Treatment Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Treatment Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Treatment Type
  • 6.4.2 By End-use
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Treatment Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Treatment Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ATRIAL FIBRILLATION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Medtronic
  • 8.2.2 Johnson & Johnson
  • 8.2.3 Abbott
  • 8.2.4 Boston Scientific
  • 8.2.5 Biotronik
  • 8.2.6 Philips
  • 8.2.7 Siemens Healthineers
  • 8.2.8 GE HealthCare
  • 8.2.9 Stryker
  • 8.2.10 IRhythm Technologies
  • 8.2.11 AliveCor
  • 8.2.12 Biosense Webster
  • 8.2.13 Acutus Medical
  • 8.2.14 AtriCure
  • 8.2.15 Kardium
  • 8.2.16 Affera
  • 8.2.17 Baylis Medical
  • 8.2.18 CathWorks
  • 8.2.19 Pulse Biosciences
  • 8.2.20 Sanofi